Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43559 | 1.00 | LMNA (0.58) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2579539 | 0.87 | LMNA (0.72) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL613704 | 0.83 | LTA4H (0.77) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL11036914 | 0.83 | LTA4H (0.77) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2091228 | 0.83 | ALDH1A1 (0.47) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2093303 | 0.83 | SIGMAR1 (0.50) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2091230 | 0.83 | ALDH1A1 (0.47) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2096705 | 0.83 | LTA4H (0.46) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2096704 | 0.83 | LTA4H (0.46) | LMNAHIF1AALDH1A1CYP2D6MAPK1 | |
| SCHEMBL2093306 | 0.83 | SIGMAR1 (0.50) | LMNAHIF1AALDH1A1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576941-B1 | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same | NISSHIN FLOUR MILLING CO (JP) | 1997-09-03 | — | — | EP | claimed |
| EP-0576941-A1 | N-benzoylamino acid derivatives, pharmaceutical compositions containing them and process for preparing same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-01-05 | — | — | EP | claimed |
| EP-0046572-B1 | 6-QUINAZOLINESULFONYL DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | claimed |
| EP-0046572-A2 | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-03-03 | — | — | EP | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-5245037-A | Synthetic bactericides | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
| EP-0393400-A1 | Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4560755-A | VASODILATOR, HYPOTENSOR | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4525589-A | Isoquinolinesulfonyl derivatives | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0061673-B1 | ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-24 | — | — | EP | disclosed |
| US-4456757-A | MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-06-26 | — | — | US | disclosed |
| EP-0061673-A1 | Isoquinolinesulfonyl derivatives and process for the preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | LMNA 451/4885HIF1A 394/4885ALDH1A1 1429/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | LMNA 2483/4885HIF1A 2291/4885ALDH1A1 1136/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | LMNA 451/4885HIF1A 394/4885ALDH1A1 1429/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | LMNA 1342/4885HIF1A 410/4885ALDH1A1 3383/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | LMNA 1342/4885HIF1A 410/4885ALDH1A1 3383/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | LMNA 451/4885HIF1A 394/4885ALDH1A1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.